日本臨牀 67/増刊6 高血圧(第4版)上巻

出版社: 日本臨牀社
発行日: 2009-10-28
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 高血圧(第4版)上巻 ―日本における最新の研究動向―
電子書籍版: 2009-10-28 (第4版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

16,280 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,280 円(税込)

目次

  • 日本臨牀 67/増刊6 高血圧(第4版)上巻

    ―目次―

    特集 高血圧(第4版)上巻 ―日本における最新の研究動向―

    I. 総論    
     1. 高血圧基礎研究の今日的課題と今後の展望
     2. 高血圧研究におけるRAA系の最新の知見と今後の展開
     3. 高血圧研究における遺伝子解析の現状と展望
     4. 高血圧研究における遺伝子改変動物の意義と問題点
     5. 新しい循環調節ペプチドの探索

    II. 我が国の世界へ発信した高血圧基礎研究の回顧    
     1. ヒト・レニンの分離・精製・遺伝子解析
     2. ヒト・アンジオテンシン-Iの分離・精製・構造決定
     3. ナトリウム利尿ペプチド研究を振り返って
     4. エンドセリンの発見
     5. アドレノメデュリンの発見
     6. Ca拮抗薬(ニフェジピン)の高血圧治療薬としての臨床開発
     7. 本態性高血圧の研究モデル動物 SHR,SHRSP の開発
        ―高血圧性疾患、‘メタボ’の成因、治療、根絶への
         新しい展望― 

    III. 血行力学・血行動態の知見    
     1. 血圧波形の物理的成因と末梢血圧からの中心血圧の推定
     2. 健常者,高血圧前症(pre-hypertension),
         高血圧患者の血行動態の変化  
     3. 家庭血圧―収縮期・拡張期血圧の今日的問題点― 
     4. 高血圧病態における中心動脈血圧の意義  
     5. 橈骨動脈脈波を用いた中心動脈血圧の評価  

    ?. 血圧調節系と高血圧成因論    
     1. 中枢神経系
     2. 自律神経系
     3. 心・血管機能調節系    
     4. 腎血圧調節系
     5. 内分泌調節系    

    ?. 循環生理活性物質の最新知見    
     1. 血管作動性物質―生合成,分泌,生理作用―    
     2. 受容体・シグナル伝達の最新知見    

    VI. 遺伝子研究    
     1. 原因候補遺伝子    
     2. 遺伝子多型    

    VII. 遺伝子改変動物に関する最新知見    
     1. レニン・アンジオテンシン系遺伝子欠損マウス 
     2. エンドセリン関連遺伝子改変動物  
     3. WKYコンジェニックラット(WKYpch1.0)  

    VIII. 臓器障害発症機序・病態生理    
     1. 脳内レニン・アンジオテンシン系  
     2. 酸化ストレス  
     3. 心血管リモデリング  
     4. メカニカルストレス  
     5. 血管細胞のアポトーシス  
     6. 血管内皮機能障害  
     7. インスリン抵抗性  
     8. 糸球体高血圧(輸入・輸出細動脈)  
     9. 尿細管糸球体フィードバック  
     10. アルドステロン・ブレイクスルー  

    IX. 高血圧病態モデル動物に関する最新知見    
     1. L-NAME投与SHR
     2. インスリン抵抗性・高血圧ラット
     3. Zucker fatty ラット高血圧モデル
     4. Dahl心不全モデルラット
     5. メタボリックシンドロームの高血圧モデル動物の開発

    ?. 新規開発高血圧治療薬の基礎研究    
     1. (プロ)レニン受容体阻害薬  
     2. エンドセリン拮抗薬  
     3. バゾペプチダーゼ阻害薬  

    XI. 降圧薬の臓器保護に関する最新知見    
     1. ARB  
     2. ACE-?  
     3. 抗アルドステロン薬  
     4. Ca拮抗薬  
     5. レニン阻害薬  

    XII. 危険因子に関する最新知見    
     1. 加齢  
     2. 性差・閉経  
     3. 肥満  
     4. 食塩  
     5. 生活習慣    

    XIII. 特論    
     1. 高血圧症における血管内皮前駆細胞の意義  
     2. 薬剤の多面的作用と血管保護  
     3. 循環器領域への新しい遺伝子改変マウス作製技術の応用
     4. AT1受容体阻害薬による認知症病態修飾の新たな視点
     5. 高血圧感受性遺伝子同定とゲノムワイド関連解析(GWAS) 
     6. 日本人の糸球体濾過量(GFR)推算式と
        我が国のCKD患者の実態  

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.15 掲載の参考文献
3) Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 : 661-678, 2007.
10) American College of Cardiology. Baroreceptor regulation for resistant hypertension. Scientific Session News, March 31, 2009. Available [http://acc09.acc.org/Documents/ACC%20D4LR.pdf.] Accessed April 28, 2009.
11) American College of Cardiology. Denervation for resistant hypertension. Scientific Session News, March 31, 2009. Available [http://acc09.acc.org/Documents/ACC%20D4LR.pdf] Accessed April 28, 2009.
12) Julius S, et al : Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 : 1685-1697, 2006.
P.20 掲載の参考文献
1) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 : 8258-8263, 2003.
2) Sarkissian SD, et al : ACE2 : A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91 : 163-198, 2006.
11) Julias S, et al : Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med 354 : 1685-1697, 2006.
P.27 掲載の参考文献
1) Rudan I, et al : Inbreeding and the genetic complexity of human hypertension. Genetics 163 : 1011-1021, 2003.
2) 加藤規弘 : 本態性高血圧の成因・病態生理-原因候補遺伝子. 臨床高血圧 (矢崎義雄, 島田和幸編), p50-54, 朝倉書店, 2002.
7) Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 : 661-678, 2007.
8) 加藤規弘 : 遺伝子情報より至適降圧薬を選択できるか? 治療学 38 : 7-11, 2004.
13) Newton-Cheh C, et al : Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 : 846-856, 2007.
P.35 掲載の参考文献
P.41 掲載の参考文献
1) Kangawa K, et al : The complete amino acid sequence ofα-neo-endorphin. Biochem Biophys Res Commun 99 : 871-878, 1981.
2) Kangawa K, et al : Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun 118 : 131-139, 1984.

II 我が国の世界へ発信した高血圧基礎研究の回顧

P.48 掲載の参考文献
10) Dealwis CG, et al : X-ray analysis at 2.0Å resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen. J Mol Biol 236 : 342-360, 1994.
15) Murakami K, et al : Prorenin converting enzymes : isolation, characterization and unique substrate specificity. In : Peptide Regulation of Cardiovascular Function (ed by lmura H, et al), p 133-143, The Takeda Science foundation, 1991.
P.54 掲載の参考文献
2) Braun-Men6ndez E, et al : La sustancia hypertensora de la sangre del rinon isquemiado. Rev Soc Arg Biol 15 : 420-425, 1939.
14) Urata H, et al : Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265 : 22348-22357, 1990.
15) Arakawa K : Presidential lecture : serine protease angiotensin II systems. J Hypertens Suppl 14 (5) : S3-S7, 1996,
16) 荒川規矩男 : ARBによるアンジオテンシン抑制の意味. Prog Med 24 : 1757-1762, 2004.
P.61 掲載の参考文献
1) 寒川賢治ほか : 新生化学実験講座9巻, p51, 東京化学同人, 1991.
2) ナトリウム利尿ペプチドファミリー (井村裕夫, 松尾寿之監), 講談社, 1995.
3) 脳とホルモン 情報をつたえるネットワーク (松尾寿之責任編集), 共立出版, 2005.
P.66 掲載の参考文献
7) Shimada K, et al : Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 269 : 18275-18278, 1994.
P.72 掲載の参考文献
P.80 掲載の参考文献
P.85 掲載の参考文献
2) Okamoto K, et al : Establishment of the stroke-prone spontaneously hypertensive rats (SHRSP). Circ Res 34, 35 (Suppl 1) : 143-153, 1974.
3) Yamori Y : Development of the spontaneously hypertensive rat (SHR), the stroke-prone SHR, the stroke-prone SHR (SHRSP) and their various substrain models for hypertension-related cardiovascular diseases. In : Handbook of Hypertension, vol 16 : Experimental and Genetic Models of Hypertension (ed by Ganten D, Jong W), p 346-364, Elsevier, Amsterdam, 1994.
4) Yamori Y : Neurogenic mechanisms of spontaneous hypertension. In : Regulation of Blood Pressure by the Central Nervous System (ed by Onesti G, et al), p 65-76, Grune & Stratton, New York, 1975.
5) Yamori Y : Physiopathology of various strains of spontaneously hypertensive rats. In : Hypertension : Physiopathology and Treatment (ed by Genest J, et al), p 556-581, McGraw-Hill, New York, 1983.
6) Korner P : SHR hypertension and its causes. In : Essential Hypertension and Its Causes (ed by Korner P), p 501-531, Oxford Univ Press, Oxford, 2007.
10) Hiraoka-Yamamoto J, et al : Establishment of a new animal model of metabolic syndrome : SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 31 (1-2) : 107-109, 2004.
11) Kitamori K, et al : Development of renal injury and lipid metabolic disorder in obese hypertensive SHR/NDmcr-cp (cp/cp). Clin Exp Hypertens 29 : 265, 2007.
12) Yasui N, et al : Enhanced monocyte chemoattractant protein 1 signaling in the early nephropathy of SHR/NDmcr-cp rats, a model of metabolic syndrome. Physiol Res 57 : 63, 2008.
14) Fujita Y, et al : Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 55 : 285-294, 2009.

III 血行力学・血行動態の知見

P.94 掲載の参考文献
P.99 掲載の参考文献
1) Drukteinis JS, et al : Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults : the Strong Heart Study. Circulation 115 : 221-227, 2007.
3) Ishikawa Y, et al : Prevalence and determinants of prehypertension in a Japanese general population : the Jichi Medical School Cohort Study. Hypertens Res 31 : 1323-1330, 2008.
P.107 掲載の参考文献
P.112 掲載の参考文献
1) Nichols W, O'Rourke MF : McDolald's Blood Flow in Arteries : Theoretical, Experimental and Clinical Principles, 4th ed, Edward Arnold, London, 1998.
2) London GM : Brachial arterial pressure to assess cardiovascular structural damage : an overview and lessons from clinical trials. J Nephrol 21 : 23-31, 2008.
9) Agaiti-Rosei E, et al : Central blood pressure measurements and antihypertensive therapy. A consensus document. Hypertension 50 : 154-160, 2007.
P.117 掲載の参考文献
3) Ogihara T, et al : The Japanese Society of Hypertension Guidehnes for the Management of Hypertension (JSH2009). Hypertens Res 32 : 3-107, 2009.
4) Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011-1053, 2003.
5) O'Rourke MF : Introduction. In : Arterial Function in Health and Disease, p 3-10, Churchill Livingstone, Edinburgh, 1982.
6) Nichols W, O'Rourke MF : McDonald's Blood Flow in Arteries. Theoretical, Experimental and Clinical Principles, 4th ed, Edward Arnold, London, 1998.
9) 高沢謙二 : 左心室収縮期後方成分の臨床的検討. 東京医科大学雑誌 45 : 256-270, 1987.
12) Takazawa K, et al : Estimation of ascending aonic pressure from radial arterial pressure using a generalised transfer function. Z Kardiol 85 : 137-139, 1996.
14) Williams B, et al ; CAFE Investigators : Anglo-Scandinavian Cardiac Outcomes Trial lnvestigators ; CAFE Steering Committee and Writing Committee : Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes : principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 : 1213-1225, 2006.
15) 高沢謙二ほか : Generalized transfer functionを用いた橈骨動脈による大動脈起始部血圧波形の推定. Therapeutic Research 17 : 1903-1913, 1996.

IV 血圧調節系と高血圧成因論

P.128 掲載の参考文献
15) Julius S, et al : Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 : 1685-1697, 2006.
P.133 掲載の参考文献
9) Quifiones-Galvan A, et al : Renal effects of insulin in man. J Nephrol 10 : 188-191, 1997.
12) Takahashi H, et al : Augmented vasodepressor and sympathetic responses to intracerebroventricular injections of diltiazem, a calcium channel blocker, in DOCA-salt hypertensive rats. J Hypertens 4 : 156-159, 1986.
P.139 掲載の参考文献
P.143 掲載の参考文献
15) Patel HH, et al : Caveolae and caveolins regulate intracellular calcium in idiopathic pulmonary arterial hypertension : a potential therapeutic role for cholesterol-losering drugs. Circulation 112 : SII-222, 2005.
P.147 掲載の参考文献
1) Touts RM, et al : Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52 : 639-672, 2000.
4) Ushio-Fukai M, et al : p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271 : 23317-23321, 1996.
P.155 掲載の参考文献
P.160 掲載の参考文献
P.167 掲載の参考文献
4) Sarkissian SD, et al : Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51 : 712-718, 2008.
14) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 : 8258-8263, 2003.
15) Tallant EA, et al : Angiotensin- (1-7) reduces hypertrophy in cardiomyocytes and hyperplasia in cardiac fibrosis. Hypertension 42 : 389, 2003.
P.172 掲載の参考文献
4) Shimamoto K, et al : Renal kallikrein-kinin, prostaglandin E2, and dopamine systems in young normotensive subjects with a family history of essential hypertension. Am J Med Sci 307 : S70-S74, 1994.
8) Tschope C, et al : Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol l29 : 1537-1538, 2000.
11) Marin-Castano ME, et al : Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105 : 627-632, 2002.
P.175 掲載の参考文献
1) 加藤堅一ほか : Cushing症候群および副腎性器症候群. 昭和57年度厚生省特定疾患「ステロイドホルモン産生異常症」調査研究班研究報告書, p6-61, 1983.
3) Williamson PM, et al : Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 14 : S37-S41, 1996.

V 循環生理活性物質の最新知見

P.183 掲載の参考文献
P.187 掲載の参考文献
5) Mizutani H, et al : Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase. J Exp Med 174 : 821-825, 1991.
10) MERCATOR Study Group : Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 86 : 100-110, 1992.
11) Peters S, et al : Valsartan for prevention of restenosis after stenting of type B2/C lesions : the VAL-PREST trial. J Invasive Cardiol 13 : 93-97, 2001,
P.192 掲載の参考文献
4) 吉村道博 : アルドステロンの異所性産生-心血管系. ホルモンと臨床 52 : 31-38, 2004.
9) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
12) 西山成ほか : アルドステロンによって生じる臓器障害と酸化ストレス : 特に腎障害作用について. YAKUGAKU ZASSHI 127 : 1331-1337, 2007.
13) 西山成ほか : アルドステロンと臓器シグナル. 医学のあゆみ 221 : 698-702, 2007.
P.198 掲載の参考文献
3) D'Orleans-Juste P, et al : Endothelin-1 (1-31) : from chymase-dependent synthesis to cardiovascular pathologies. Vascul Pharmacol 49 : 51-62, 2008.
P.202 掲載の参考文献
1) 平田恭信 : NO. 日本臨牀 64 (増刊号5) : 254-258, 2006.
P.207 掲載の参考文献
1) 田村尚久, 中尾一和 : ナトリウム利尿ペプチド. 日本臨牀 64 (増刊号5) : 117-121, 2006.
P.211 掲載の参考文献
6) 加藤丈司, 北村和雄 : 循環器疾患とアドレノメデュリン. ペプチドと創薬 (寒川賢治, 南野直人編), p116-119, メディカルドゥ, 2007.
10) 北村和雄ほか : PAMP単独過剰発現ラットの開発とPAMPの血管新生作用. 日内分泌会誌 82 : 116, 2006.
P.215 掲載の参考文献
P.219 掲載の参考文献
2) Chalmers JP, et al : Serotonergic mechanisms in hypertension. In : Endocrine Mechanisms in Hypertension (ed by Laragh JH, et al), p 241-264, Raven Press, New York, 1989.
6) Hoyer D, et al : International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46 : 157-203, 1994.
10) Soares-da-Silva P, et al : Antagonistic actions of renal dopamine and 5-hydroxytryptamine : increase in Na+, K+ -ATPase activity in renal proximal tubules via activation of 5-HT, A receptors. Br J Pharmacol 117 : 1199-1203, 1996.
12) Soares-da-Silva P, et al : Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens Res 18 (Suppl 1) : S47-51, 1995.
P.226 掲載の参考文献
P.231 掲載の参考文献
P.237 掲載の参考文献
P.241 掲載の参考文献
6) Watanabe T, et al : Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res 31 : 463-468, 2008.
7) Watanabe T, et al : Impact of salusin-α and-β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 117 : 638-648, 2008.
10) Saito T, et al : Chronic osmotic stimuli increase salusin-β-like immunoreactivity in the rat hypothalamo-neurohypophyseal system : possible involvement of salusin-βon [Ca2+] i increase and neurohypophyseal hormone release from the axon terminals. J Neuroendocrinol 20 : 207-219, 2008.
P.245 掲載の参考文献
1) Yu JX, et al : Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem 269 (29) : 18843-18848, 1994.
5) Adachi M, et al : Activation of epithelial sodium channels by prostasin in Xenopus oocytes. J Am Soc Nephrol 12 (6) : 1114-1121, 2001.
9) Wakida N, et al : Inhibition of prostasin-induced ENaC activities by PN-1 and regulation of PN-1 expression by TGF-betal and aldosterone. Kidney Int 70 (8) : 1432-1438, 2006.
P.250 掲載の参考文献
P.257 掲載の参考文献
P.261 掲載の参考文献
1) Hotamisligil GS, et al : Adipose expression of tumor necrosis facto卜alpha : direct role in obesity-linked insulin resistance. Science 259 : 87-91, 1993.
P.267 掲載の参考文献
13) 佐藤哲子, 小川佳宏 : 脂肪細胞と血管壁のクロストーク (アディポネクチンを含めて). 血管医学 10 (1) : 25-32, 2009.
P.271 掲載の参考文献
1) McCully KS : Vascular pathology of homocysteinemia. Am J Pathol 56 : 111-128, 1969.
5) Denesh J, Lewington S : Plasma homocysteine and coronary heart disease : systematic review of published epidemiological studies. J Cardiovasc Risk 5 : 229-232, 1998.
9) Klerk M, et al : MTHFR 677C→T polymorphism and risk of coronary heart disease. JAMA 288 : 2023-2031, 2002.
11) Chauveau P, et al : Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 41 : S72-S77, 1993.
P.277 掲載の参考文献
P.281 掲載の参考文献
5) Massry SG, et al : Parathyroid hormone as a uremic toxin. In : Textbook of Nephrology (ed by Massry SG, et al), p 1126-1144, Williams & Wilkins, Baltimore, 1989.
P.287 掲載の参考文献
P.292 掲載の参考文献
1) Gasparo M, et al : International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 : 415-472, 2000.
10) Zhai P, et al : Cardiac-specific overexpression of AT1 receptor mutant lacking Gαq/Gαi coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115 : 3045-3056, 2005.
11) LyngsσC, et al : Functional interactions between 7TM receptors in the renin-angiotensin system-dimerization or crosstalk? Mol Cell Endocrinol 302 : 203-212, 2009.
13) Fu GD, et al : The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 11 : 165-180, 2001.
P.298 掲載の参考文献
7) AbdAlla S, et al : Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem 284 : 6554-6565, 2009.
17) D'Amore A, et al : The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46 : 1347-1354, 2005.
P.302 掲載の参考文献
P.308 掲載の参考文献
P.312 掲載の参考文献
2) Verricr E, et al : PPARγ agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway : role of diacylglycerol kinase. Circ Res 94 : 1515-1522, 2004.
5) Kubota N, et al : PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 : 597-609, 1999.
P.318 掲載の参考文献
4) Dragun D, et al : Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352 : 558 -569, 2005.
18) Felder RA, et al : Gprotein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 99 : 3872-3877, 2002.
24) Iiri T, et al : G-protein diseases furnish a model for the turn-on switch. Nature 394 : 35-38, 1998.
P.324 掲載の参考文献
P.328 掲載の参考文献
1) Matsui T, et al : Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15 : 2208-2216, 1996.
3) Ishizaki T, et al : The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15 : 1885-1893, 1996.
P.335 掲載の参考文献
4) Hardie DG : New roles for the LKB1→AMPK pathway. Curr Opin Cell Biol 17 : 167-173, 2005.

VI 遺伝子研究

P.342 掲載の参考文献
7) Villard E, et al : A mutant renin gene in familial elevation of prorenin. J Biol Chem 269 : 30307-30312, 1994.
13) Mtiller DN, et al : Aliskiren-mode of action and preclinical data. J Mol Med 86 : 659-662, 2008.
P.347 掲載の参考文献
23) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Bio1 6 : 499-506, 2004.
P.353 掲載の参考文献
11) Martin MM, et al : The human angiotensin II type 1 receptor+ 1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem 282 : 24262-24269, 2007.
21) AbdAlla S, et al : Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem 284 : 6554-6565, 2009.
25) Pedersen-Bjergaard U, et al : Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes. Am J Med 121 : 246. el-246. e8, 2008.
P.357 掲載の参考文献
P.362 掲載の参考文献
1) 田中廣壽ほか : ステロイド薬の作用機序. Modern Physician, 2009. (印刷中)
8) Rosmund R : The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res 10 : 1078-1086, 2002.
P.366 掲載の参考文献
5) Eng MY, et al : ALDH2, ADH1B, and ADH1C genotypes in Asians : a literature review. Alcohol Res Health 30 : 22-27, 2007.
7) Okayama A, et al : Low-Km aldehyde dehydrogenase deficiency does not influence the elevation of blood pressure by alcohol. J Hum Hypertens 8 : 205-208, 1994.
P.370 掲載の参考文献
P.374 掲載の参考文献
1) 小川渉, 春日雅人 : インスリン作用機構と糖尿病. 生化学 75 : 1332-1344, 2003.
14) Frayling TM, et al : A common variant in the FrO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316 : 889-894, 2007.
P.379 掲載の参考文献
P.383 掲載の参考文献
1) 戸谷義幸ほか : αアドレナリン受容体遺伝子. 日本臨牀 64 (増刊号5) : 379-384, 2006.
8) O'Connell TD, et al : Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 116 : 1005-1015, 2006.
10) Buscher R et al : Variability in phenylephrine response and essential hypertension : a search for human alpha (1B) -adrenergic receptor polymorphisms. J Pharmacol Exp Ther 291 : 793-798, 1999.
P.390 掲載の参考文献
2) Brodde O-E : β-1 and β-2 adrenoceptor polymorphisms : functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 117 : 1-29, 2008.
3) Btischer R, et al : Human adrenoceptor polymorphisms : evolving recognition of clinical importance. Trend Pharmacol Sci 20 : 94-99, 1999.
5) Hahntow IN, et al : The β2-adrenoceptor gene and hypertension : is it the promoter or the coding region or neither? J Hypertens 24 : 1003-1007, 2006.
6) Iaccarino G, et al : The Glu27 allele of the β2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertens 22 : 2117-2122, 2004.
7) Sethi AA, et al : 164Ile allele in the β2-adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study. Pharrnacogenet Genomics 15 : 633-645, 2005.
P.395 掲載の参考文献
P.398 掲載の参考文献
8) Pinto-Sietsma SJ, et al : Role of the endothelin-1 gene locus for renal impairment in the general nondiabe6c population. J Am Soc Nephrol 14 : 2596-2602, 2003.
9) Funke-Kaiser H, et al : Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. Hum Mol Genet 12 (4) : 423-433, 2003.
P.404 掲載の参考文献
P.408 掲載の参考文献
3) Imura A, et al : α-klotho as a regulator of calcium homeostasis. Science 316 : 1615-1618, 2007.
9) Kurose H, et al : Suppression of aging in mice by the hormone klotho. Science 309 : 1829-1833, 2005.
10) Aizawa H, et al : Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 249 : 865-871, 1998.
P.412 掲載の参考文献
5) Jia H, et al : Association of the G (s) alpha gene with essential hypertension and response to beta-blockade. Hypertension 34 : 8-14, 1999.
16) Peppel K, et al : Overexpression of G protein-coupled receptor kinase-2 in smooth muscle cells reduces neointimal hyperplasia. J Mol Cell Cardiol 34 : 1399-1409, 2002.
P.417 掲載の参考文献
2) Yoshimura M, et al : Amissense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103 : 65-69, 1998.
3) Nakayama M, et al : AT-786→C mutation in the 5'-fianking region of the endothelial nitric oXide synthase gene is associated with coronary spasm. Circulation 99 (22) : 2864-2870, 1999.
5) Miyamoto Y, et al : Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a T-786→C mutation associated with coronary spastic angina. Hum Mol Genet 9 (18) : 2629-2637, 2000.
6) Yoshimura M, et al : Genetic risk factors for coronary artery spasm : significance of endothelial nitric oxide synthase gene T-786→C and missense Glu298Asp variants. J Invest Med 48 (5) : 367-374, 2000.
7) Yoshimura M, et al : AT-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene and coronary arterial vasomotility. Am J Cardiol 85 : 710-714, 2000.
P.425 掲載の参考文献
6) 杉山徹, 平田結喜緒 : 心房性ナトリウム利尿ペプチド遺伝子. 日本臨牀 64 (増刊号5) : 417-422, 2006.
10) Wang D, et al : Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105 : 851-862, 2002.
P.430 掲載の参考文献
P.435 掲載の参考文献
1) Folkman J : Tumor angiogenesis : therapeutic implication. N Engl J Med 285 : 1182-1186, 1971.
2) O'Reilly MS, et al : Angiostatin : a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 : 315-328, 1994.
3) Chen C, et al : A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 268 : 4230-4233, 1995.
4) Brooks PC, et al : Requirement of vascular integrin αvβ3 for angiogenesis. Science 264 : 569-571, 1994.
7) Hurwitz H, et al : Bevacizumab plus irinotecan, fiuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 : 2335-2342, 2004.
P.441 掲載の参考文献
P.445 掲載の参考文献
P.453 掲載の参考文献
12) O'Donnell CJ, et al : Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97 : 1766-1772, 1998.
15) Agerholm-Larsen B, et al : ACE gene polymorphism in cardiovascular disease : meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 20 : 484-492, 2000.
P.458 掲載の参考文献
10) Sugimoto K, et al : Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension : the Ohasama Study. Hypertens Res 27 : 551-556, 2003.
12) Coll E, et al : Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol 16 : 357-364, 2003.
16) Kurland L, et al : The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism : results from the Swedish Irbesartan Left『Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens 21 : 836-839, 2008.
P.462 掲載の参考文献
P.468 掲載の参考文献
1) Emorine LJ, et al : Molecular characterization of the human β3-adrenergic receptor. Science 245 : 1118-1121, 1989.
2) 斉藤昌之 : 褐色脂肪とメタボリックシンドローム. 実験医学 25 : 2291-2297, 2007.
3) Walston J, et al : Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333 : 343-347, 1995.
4) Widen E, et al : Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333 : 348-351, 1995.
5) Yoshida T, et al : Mutation of β3-adrenergic-receptor gene and response to treatment of obesity. Lancet 346 : 1433-1434, 1995.
6) Yoshioka K, et al : Association of Trp64Arg mutation in the β3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia 39 : 1410, 1996.
7) Kadowaki H, et al : Amutation of β3-adrenergic-receptor gene is associated With obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 215 : 555-560, 1995.
8) Sakane N, et al : β3-adrenergic-receptor polymorphism : a genetic marker for visceral fat obesity and insulin resistance syndrome. Diabetologia 40 : 200-204, 1997.
9) Kimura K, et al : Mutated human β3-adrenergic receptor (Trp64Arg) lowers the response to β3-adrenergic agonists in transfected 3T3-L1 preadipocytes. Horm Metab Res 32 : 91-96, 2000.
10) Umekawa T, et al : Trp64Arg mutation of β3-adrenoceptor gene deteriorates lipolysis induced by β3-adrenoceptor agonist in human omental adipocytes. Diabetes 48 : 117-120, 1999.
11) Kogure A, et al : Synergic effect of polymorphisms in uncoupling protein 1 and β3-adrenergic receptor genes on weight loss in obese Japanese. Diabetologia 41 : 1399, 1998.
12) Kawaguchi H, et al : β2- and β3-Adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res 29 : 951-959, 2006.
13) 森由弘ほか : 睡眠時無呼吸症候群とβ3アドレナリンレセプター遺伝子多型. 分子呼吸器病学 11 : 116-120, 2007.
14) 村上英之, 島本和明 : 高血圧とインスリン抵抗性. インスリン抵抗性, p58-64, 医学書院, 2006.
15) Tonolo G, et al : Association of Trp64Arg β3-adrenergic-receptor gene polymorphism with essentioal hypertension in the Sardinian population. J Hypertens 17 : 33-38, 1999.
16) 吉田俊秀 : 肥満症の遺伝子診断-テーラーメイド型食事指導への応用. 医学のあゆみ 213 : 837-840, 2005.
P.472 掲載の参考文献
1) 大木元明義, 檜垣實男 : G蛋白質 (β3サブユニット) 遺伝子多型. 日本臨牀 64 (増刊号5) 450-454, 2006.
18) Lelonek M, et al : A novel approach to syncopal patients : association analysis of polymorphisms in G-protein genes and tilt outcome. Europace 11 : 89-93, 2009.
19) Siffert W, et al : Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 10 : 1921-1930, 1999.
24) Fernandez-Real JM, et al : G protein beta3 gene variant, vascular function, and insulin sensitivity in type 2 diabetes. Hypertension 41 : 124-129, 2003.
P.477 掲載の参考文献
2) Nakayama M, et al : T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 : 2864-2870, 1999.
3) Miyamoto Y, et al : Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a-786T→C mutation associated with coronary spastic angina. Hum Mol Genet 9 : 2629-2637, 2000.
11) Kajiyama N, et al : Lack of association between T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene and essential hypertension. Hypertens Res 23 : 561-565, 2000.

VII 遺伝子改変動物に関する最新知見

P.484 掲載の参考文献
1) Tanimoto K, et al : Angiotensinogen-deficient mice with hypotension. J Biol Chem 269 : 31334-31337, 1994.
P.487 掲載の参考文献
3) Clouthier DE, et al : Cranial and cardiac neural crest defects in endothelin -A receptor-deficient mice. Development 125 : 813-824, 1998.
P.494 掲載の参考文献
1) 並河徹 : 高血圧遺伝子解析におけるコンジェニックラットの意義. 日本臨牀 59 : 832-835, 2001.
2) 並河徹 : SHRSP由来の第1染色体コンジェニックラットにおけるストレス反応の亢進. 血圧 9 : 341-344, 2002.
10) 仲本みのりほか : コンジェニックラット (WKYpch1.0) における慢性的な環境ストレス負荷による血圧への影響. 第31回日本高血圧学会総会抄録集, p268, 2008.

VIII 臓器障害発症機序・病態生理

P.499 掲載の参考文献
6) Oztas B, Sandalci U : Reversibility of blood-brain barrier dysfunction in acute hypertension induced by angiotensin. Exp Neurol 84 : 666-670, 1984.
8) Fleegal-DeMotta MA, et al : Angiotensin II modulates BBB permeability via activation of the AT1 receptor in brain endothelial cells. J Cereb Blood Flow Metab 29 : 640-647, 2009.
24) Vervoort VS, et al : AGTR2 mutations in X-linked mental retardation. Science 296 : 2401-2403, 2002.
25) von Bohlen O, Halbach O : Angiotensin IV in the central nervous system. Cell Tissue Res 311 : 1-9, 2003.
P.505 掲載の参考文献
P.513 掲載の参考文献
P.518 掲載の参考文献
3) Akazawa H, Komuro I : Mechanical stress induces cardiomyocyte hypertrophy through agonist-independent activation of angiotensin II type 1 receptor. In : Mechanosensitivity in Cells and Tissues Vol 3 Mechanosensitivity of the Heart (ed by Kamkin A, Kiseleva I), Springer, Berlin. (in press)
P.524 掲載の参考文献
10) Suhara T, et al : Hydrogen peroxide induces up-regulation of Fas in human endothelial cells. J Immunol 160 : 4042-4047, 1998.
P.528 掲載の参考文献
P.532 掲載の参考文献
1) UK Prospective Diabetes Study Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998.
6) Lansberg L : Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome. Ann N Y Acad Sci 892 : 84-90, 1999.
11) Fontbonne A, et al : Coronary heart disease mortality risk : plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes 12 : 557-565, 1988,
14) 大西浩文ほか : 地域男性住民における日本の診断基準によるメタボリックシンドロームと心イベントとの関連-端野・壮瞥町研究-. 医学のあゆみ 219 : 807-809, 2006.
P.537 掲載の参考文献
2) Hayashi K, et al : Role of Ca channel subtypes in the renal microcirculation with special references to kidney injury. Organ Microcirculation-A Gateway to Diagnostic and Therapeutic Interventions. International Symposia for Life Science and Medicine Vol 13, p 225-232, 2004.
4) Hayashi K, et al : Renal hemodynamic effects of calcium antagonists. In : Calcium Antagonists in Clinical Medicine, 3rd ed, p 559-578, Hanley & Belfus, Philadelphia, 2002.
P.541 掲載の参考文献
1) Thurau K, Schnemlann J : The sodium concentration in the macula densa cells as a regulating factor for glomerular filtration (micropuncture experiments). Klin Wochenschr 43 : 410-413, 1965.
8) Nishiyama A, Navar LG : ATP mediates tubuloglomerular feedback. Am J Physiol 283 : R278-R279, 2002.
11) Kovacs G, et al : Angiotensin II directly stimulates macula densa Na-2Cl-K cotransporter via apical AT (1) receptors. Am J Physiol 282 : F301-F306, 2002.
P.547 掲載の参考文献
13) 田辺晶代ほか : AT1拮抗薬 (ARB) の長期投与によるアルドステロン・ブレークスルーとその病態生理学的意義-本態性高血圧症における検討-. ホルモンと臨床 52 : 41, 2004.
16) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.

IX 高血圧病態モデル動物に関する最新知見

P.556 掲載の参考文献
1) 中田徹男 : NOの役割と臓器障害. 京府医大誌 117 (4) : 243-254, 2008.
2) 平田恭信 : 高血圧性臓器障害に関する基礎研究-NO. 日本臨牀 62 (増刊号3) : 243-246, 2004.
11) Hsu YH, et al : Malignant alterations following early blockade of nitric oxide synthase in hypertensive rats. Chin J Physiol 50 : 283-293, 2007.
16) Kameda T, et al : Efonidipine, a calcium channel blocker, alleviates renal injury induced by nitric oxide synthase inhibition in spontaneously hypertensive rats. Dokkyo J Med Sci 36 : 9-16, 2009.
35) Yang YL, et al : Endothelin and gelatinases in renal changes following blockade of nitric oxide synthase in hypertensive rats. Chin J physiol 51 : 186-195, 2008.
P.562 掲載の参考文献
11) Tobian L : The protective effect of high-potassium diet in hypertension, and the mechanisms by which high-NaCl diet produce hypertension-Apersonal view. In : Hypertension : Pathophysiology, Diagnosis and Management, 2nd ed, p 299-312, Raven Press, New York, 1995.
P.567 掲載の参考文献
11) Watanabe S, et al : Blunted pressure-natriuresis and decreased renal medullary blood flow in obese Zucker rats. J Med Soc Toho Univ 55 : 270-277, 2008.
P.576 掲載の参考文献
6) Onozato ML, et al : Dual blockade of aldosterone and angiotensin II additively suppresses TGF-β and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 22 : 1314-1322, 2007.
7) Yoshida K, et al : Cardioprotective mechanisms of combination therapy with selective aldosterone blocker and ARB associated with JAK-STAT pathway in failing rat hearts. Circ J 69 (Suppl 1) : 483, 2005.
P.580 掲載の参考文献
6) Nakamura M : Adiabetic strain of the mouse. Proc Jpn Acad 38 : 348, 1962.
11) Hansen CT : The development of the SHR/N-and LA/N-cp (corpulent) congenic rat strains. In : New Models of Genetically Obese Rats for Studies in Diabetes, Heart Disease, and Complications of Obesity. Summaries of Workshop Papers and Current Bibliography (ed by Hansen CT, Michaelis OE IV), p 7-10, National lnstitutes of Health, Bethesda Md, 1988.
12) Hiraoka-Yamamoto J, et al : Establishment of a new animal model of metabolic syndrome : SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 31 : 107-109, 2004.

X 新規開発高血圧治療薬の基礎研究

P.587 掲載の参考文献
7) Derkx F, Schalekamp M : Human prorenin : pathophysiology and clinical implications. Clin Exp Hypertens A 10 : 1213-1225, 1988.
P.592 掲載の参考文献
4) Rubanyi GM, Polokoff MA : Endothelins : molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46 : 325-415, 1994.
P.596 掲載の参考文献
8) Emoto N : Physiological and pathophysiological roles of the endothelin converting enzymes. Nippon Rinsho 62 : 636-639, 2004.
11) Daull P, et al : Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med 231 : 830-833, 2006.
12) Daull P, et al : The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601. Exp Biol Med 231 : 824-829, 2006.

XI 降圧薬の臓器保護に関する最新知見

P.604 掲載の参考文献
1) Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (1) : 11-34, 2000.
P.611 掲載の参考文献
1) Yusuf S, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (15) : 1547-1559, 2008.
2) Matchar DB, et al : Systematic review : comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148 (1) : 16-29, 2008.
13) Yoshiji H, et al : Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. Oncol Rep 14 (1) : 213-218, 2005.
22) Hernandez-Guerra M, et al : Increased hepatic resistance : a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 39 (4 Suppl 2) : S131-137, 2005.
P.616 掲載の参考文献
5) Garthwate SM, McMahon EG : The evolution of aldosterone antagonists. Mol Cell Endocrinol 217 : 27-31, 2004.
P.621 掲載の参考文献
4) Staessen JA, et al : Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 : 757-764, 1997.
P.626 掲載の参考文献
15) Mann JF, et al : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) : a multicentre, randomised, double-blind, controlled trial. Lancet 372 : 547-553, 2008.

XII 危険因子に関する最新知見

P.635 掲載の参考文献
P.639 掲載の参考文献
1) 国民栄養の現状 (平成17年厚生労働省国民栄養調査結果) (健康・栄養情報研究会編), p1-236, 第一出版, 2008.
2) 上園慶子, 平田恭信 : 女性における虚血性心疾患の危険因子と予防. 女性における虚血性心疾患-成り立ちからホルモン補充療法まで (天野恵子, 大川真一郎編), p86-94, 医学書院, 2000.
6) 藤井潤 : 老人の臨床検査の正常値. 日老医誌 31 : 262-269, 1994.
7) 上園慶子 : 血圧検査. 学生の健康白書2005 (学生の健康白書作成に関する特別委員会編), p41-62, 国立大学等保健管理施設協議会, 2008.
8) 猿田享男 : 妊娠と高血圧. からだの科学増刊 高血圧 (藤井潤編), p50-53, 1993.
10) 谷崎弓裕ほか : 久山町の地域住民におけるJNCの血圧分類とタイプ別脳梗塞発症率の関係. 第21回日本高血圧学会総会-プログラム・抄録集-, p22, 1998.
13) 上田一雄 : 久山町研究30年間の流れと循環器病の変遷. 循環器病予防の戦略 久山町研究30周年記念講演集 (尾前照雄ほか編), p81-98, 大道学館, 1993.
P.643 掲載の参考文献
3) Ogaden CL, et al : Prevalence of overwight and obesity in th e United States 1999-2004. JAMA 295 : 1549-1555, 2006.
4) Sa'nchez -Castillo CP, et al : Diabetes and hypertension increases in a society with abdominal obesity : results of the Mexican National Health Survey 2000. Public Health Nutr 8 (1) : 53-60, 2005.
6) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2009, ライフサイエンス出版, 2009.
P.647 掲載の参考文献
P.652 掲載の参考文献
1) Lewington S, et al : Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 : 1903-1913, 2002.
2) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 生活習慣の修正. 高血圧治療ガイドライン 2009, p31-36, ライフサイエンス出版, 2009.
6) 石光俊彦ほか : 高カリウム食による高血圧ラットにおける血管内膜障害の抑制. 脈管学 40 : 281-285, 2000.
9) MacCarron DA, et al : Blood pressure and nutrient intake in the United States. Science 224 : 1392-1398, 1984.
16) Hofmeyr GJ, et al : Calcium supplementation to prevent pre-eclampsia-A systematic review. S Afr Med J 93 : 224-228, 2003.
19) Corsonello A, et al : Serum magnesium levels and cognitive impairment in hospitalized hypertensive patients. Magnesium Res 14 : 273-282, 2001.
22) National High Blood Pressure Education Program Coordinating Committee : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
25) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
29) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 生活習慣の修正. 高血圧治療ガイドライン 2004, p22-27, ライフサイエンス出版, 2004.
P.657 掲載の参考文献
1) Lian C : L' alcoholisme, cause d'hypertension arterielle. Bull Acad Natl Med (Paris) 74 : 525-528, 1915.
14) Hsieh ST, et al : Magnesium supplementation prevents alcohol-induced hypertension. Hypertension 19 : 175-182, 1993.
20) Ueshima H, et al : The effect of reduced alcohol consumption on blood pressure : a randomized controlled single blind study. J Hum Hypertens 1 : 113-119, 1987.
25) Jankowsky P, et al : Detemlinants of poor hypertension management in patients with ischemic heart disease. Blood Press 14 : 284-292, 2005.
P.663 掲載の参考文献
8) Minami J, et al : Is it time to regard cigarette smoking as a risk factor in the development of sustained hypertension? Am J Hypertens 12 : 948-949, 1999.
P.670 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 2009.
3) Tanaka H, Shindo M : Prevalence Rate of Hypertension in Relation to Physical Fitness, Elsevier Science Publisher, Amsterdam, 1990.
4) Kukkonen K, et al : Physical training of middle-aged men with borderline hypertension. Ann Clin Res 14 (Suppl 34) : 139-145, 1982.

XIII 特論

P.678 掲載の参考文献
5) Balin AK, et al : Effects of establishing cell cultures and cell culture conditions on the proliferative life span of human fibroblasts isolated from different tissues and donors of different ages. Exp Cell Res 274 : 275-287, 2002.
P.683 掲載の参考文献
4) Yoshida K et al : Effects of benidipine, a calcium antagonist, on urinary kallikrein excretion and renal impairment in experimental diabetes. J Hypertens 14 : 215-222, 1996.
14) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
P.689 掲載の参考文献
P.694 掲載の参考文献
8) Yusuf S, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008.
13) Wang J, et al : Valsartan lowers brain beta-amyloid protein 1evels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117 : 3393-3402, 2007.
15) 武田朱公ほか : 神経年齢とRAS-認知症に対する新たな治療ターゲットとしての可能性を探る-. Angiotensin Research 6 : 31-37, 2009.
P.699 掲載の参考文献
P.703 掲載の参考文献
1) National Kidney Foundation : K/DOQI clinical practice guidelines for chronic kidney disease : Evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppl 2) : S1-S266, 2002.
3) 折田義正ほか : イヌリンクリアランスを用いた糸球体濾過量の評価-クレアチニンクリアランスとの比較-. 日腎会誌 46 : 804-812, 2005.
14) 今井圓裕 : 日本人の腎機能, 第51回日本腎臓学会学術総会教育講演, 2008.
15) CKD患者を専門医に紹介するタイミング. CKD診療ガイド (日本腎臓学会編), p 50-51, 東京医学社, 2007.

最近チェックした商品履歴

Loading...